Complete removal of a corneal scar is rarely achievable with current treatments, but the scar can often be reduced enough to restore useful vision. The outcome depends heavily on how deep the scar sits in the cornea, how wide it is, and whether it overlaps with your line of sight. Shallow scars respond well to laser procedures and minor surgery, while deep or dense scars may require a corneal transplant or, in some cases, an artificial cornea. The honest picture is a spectrum: some people walk away with near-normal clarity, others see meaningful improvement without the scar disappearing entirely, and a small number face scars too severe for any current technique to fully reverse.
Why the Cornea Scars in the First Place
The cornea is the clear, dome-shaped window at the front of your eye. It gets its transparency from an unusually precise arrangement of collagen fibers in its middle layer, the stroma. When an infection, injury, burn, or surgery damages that layer, the body sends in repair cells called myofibroblasts. These cells produce large amounts of disorganized collagen and other structural proteins, which scatter light instead of transmitting it cleanly. That disorganized tissue is the scar.1PubMed Central. Corneal myofibroblasts and fibrosis The signal that triggers this fibrotic cascade is a growth factor called TGF-β, which is released by the surrounding epithelium, tears, and other stromal cells.2PubMed. TGF-β1-mediated upregulation of LMCD1 drives corneal myofibroblast differentiation and corneal fibrosis
A critical detail is a thin, tough sheet called Bowman’s layer that sits just beneath the surface epithelium. Once Bowman’s layer is breached, scar tissue tends to form in and beneath the gap, anchoring fibrosis deeper into the stroma.3PubMed. Corneal wound healing from the perspective of keratoplasty specimens with special reference to the function of the Bowman layer and Descemet membrane This is one reason superficial scratches often heal without a visible mark while deeper injuries leave lasting haze: once that protective barrier is gone, the scarring process has a direct route into the corneal interior.
How Depth and Location Determine Your Options
The cornea is only about 500 to 550 micrometers thick at its center. Scar depth is measured against that total, and treating a scar always means weighing how much tissue you can safely remove or reshape without dangerously thinning the cornea. Doctors use imaging tools like optical coherence tomography (OCT) to map the exact depth, width, and density of a scar before planning any procedure.4PubMed Central. Optical coherence tomography and ultrasound biomicroscopy imaging of opaque corneas In one clinical case, OCT line scans revealed a scar extending to 165 micrometers deep with overlying epithelium thickened to 96 micrometers, and those measurements directly guided the laser treatment plan.5Ophthalmology. High-Speed Optical Coherence Tomography of Corneal Opacities
Location matters just as much. A scar off to the periphery of the cornea may cause almost no vision loss, while a scar sitting right over the pupil can be devastating. And a scar that extends across a wide swath of the cornea limits the number of treatments that can address it without altering the eye’s curvature and introducing new refractive problems. Broadly, the shallower and smaller the scar, the better the prognosis. Scars confined to the front fifth or so of the cornea are the best candidates for laser and minor surgical treatments. Scars that reach deeper usually require more involved surgery.
Laser Treatment for Shallow Scars
The most common laser approach for corneal scars is phototherapeutic keratectomy, or PTK. An excimer laser precisely vaporizes tissue layer by layer, smoothing out the irregular scar surface. PTK works best on superficial opacities. In a study of patients with various superficial corneal opacities, the average ablation depth was about 78 micrometers, though some cases required removing up to 200 micrometers of tissue.6PubMed Central. Phototherapeutic Keratectomy Outcomes in Superficial Corneal Opacities That represents a meaningful chunk of corneal thickness, which is why surgeons are cautious about how deep they go.
For scars that reach beyond the front fifth of the cornea, PTK can still help, but the goal shifts from total removal to smoothing and reducing the opacity. The smoothing effect improves how evenly light passes through the cornea, which can lower astigmatism and improve functional vision even if some haze remains.7PubMed Central. Pentacam-based phototherapeutic keratectomy outcome in superficial corneal opacities In many cases, this partial improvement is enough to avoid a corneal transplant altogether.
Some surgeons combine PTK with a manual procedure called superficial lamellar keratectomy, where a thin blade or automated instrument peels away the scarred tissue before the laser smooths what remains. This combination has shown significant improvements in both corneal clarity and visual sharpness for scars caused by trauma, previous surgery, or infection.8PubMed Central. Automated superficial lamellar keratectomy augmented by excimer laser masked PTK in the management of severe superficial corneal opacities
Superficial Keratectomy Without a Laser
Not every scar needs a laser. Superficial keratectomy, which involves manually scraping or cutting away the scarred surface tissue, remains a workhorse technique for conditions ranging from corneal dystrophies to post-traumatic scarring and retained foreign bodies.9PubMed Central. Superficial Keratectomy: A Review of Literature The procedure is relatively straightforward and can be performed in an outpatient setting. When combined with an amniotic membrane graft placed over the raw surface, healing tends to be faster and surface quality improves. In one series, eyes treated with superficial keratectomy and a cryopreserved amniotic membrane re-epithelialized in an average of seven days, with a significant reduction in higher-order optical aberrations at the two-month mark.10PubMed Central. Superficial Keratectomy with Cryopreserved Amniotic Membrane for Ocular Surface Optimization in Patients with Epithelial Basement Membrane Dystrophy
The limitation is the same as with PTK: the scar has to be shallow enough that removing it does not compromise the structural integrity of the cornea. If the opacity dives into the deeper stroma, scraping the surface clean simply is not going to reach it.
When You Need a Corneal Transplant
For scars that extend deep into the stroma or span most of the cornea’s diameter, transplantation is often the only route to meaningful visual recovery. The two main options are deep anterior lamellar keratoplasty (DALK), where the surgeon replaces the front layers of the cornea while keeping the patient’s own inner lining, and penetrating keratoplasty (PK), where the full thickness of the cornea is replaced.
DALK has gained ground over PK in recent years because keeping the patient’s own endothelium (the innermost cell layer) lowers the risk of graft rejection. In a comparison of the two techniques in eyes with corneal scarring from keratoconus-related hydrops, DALK produced visual and refractive outcomes comparable to PK while carrying fewer serious complications.11PubMed. Comparison of Deep Anterior Lamellar Keratoplasty and Penetrating Keratoplasty in Keratoconic Eyes With Previous Hydrops-Related Corneal Scar The “big-bubble” technique used in DALK also tends to produce better corneal clarity in the posterior layer compared to manual dissection methods, translating into somewhat sharper vision.12PubMed. Comparison of Corneal Densitometry Between Penetrating Keratoplasty and Deep Anterior Lamellar Keratoplasty in Keratoconus Patients
Transplants can deliver dramatic visual improvement, but they come with a long recovery period, a lifelong need for follow-up, and the possibility of graft rejection even years later. There is also the practical problem of donor tissue supply: the global shortage of transplantable donor corneas means many patients, particularly in low- and middle-income countries, wait months or years for surgery.13PubMed Central. Regenerative Therapy for Corneal Scarring Disorders
The Role of Amniotic Membrane in Reducing Scars
Amniotic membrane, the innermost layer of the placenta, has become one of the more versatile tools in corneal surgery. When placed over a healing wound, it suppresses the inflammatory signals that drive scarring. It does this partly by blocking TGF-β signaling in fibroblasts, which prevents those cells from turning into the scar-producing myofibroblasts described earlier.14PubMed Central. Amniotic Membrane Transplantation for Wound Healing, Tissue Regeneration and Immune Modulation It also creates a locally immunosuppressive environment by driving inflammatory cells toward an anti-inflammatory profile, reducing the cytokine storm that worsens fibrosis.
Amniotic membrane transplantation is often used as an adjunct after a keratectomy or chemical burn rather than as a standalone scar-removal technique. In severe cases like total corneal scarring from chemical injury, it has been combined with limbal stem cell transplantation to rebuild the eye’s surface from scratch, offering a path back toward corneal clarity and function.15International Surgery Journal. Management of chemical injury with total corneal scar and cicatrization treated with simple limbal epithelial transplantation and amniotic membrane transplantation: a case report The membrane is not removing an existing scar in the way a laser does; instead, it is helping the cornea heal with less scarring than it otherwise would. That makes it most valuable during the acute phase after injury or as a biological dressing after surgical scar removal.
Emerging Drug and Biologic Treatments
Because TGF-β is the central villain in corneal fibrosis, researchers have been looking for ways to block it pharmacologically. One early clinical experience used topical losartan, a drug familiar from blood-pressure management, as a TGF-β inhibitor applied directly to the eye. In patients who developed clinically significant haze after collagen cross-linking for keratoconus, topical losartan appeared to reduce the haze, though the authors stressed that larger clinical trials are still needed.16PubMed. Topical Losartan for Treating Corneal Haze After Ultraviolet-A/Riboflavin Collagen Cross-Linking If validated, a topical drug that can be applied like an eye drop would be a major step forward: it would let doctors intervene during the window when the scar is forming, before it becomes permanent.
Mesenchymal stem cell exosomes are another promising line of research. These are tiny vesicles shed by stem cells that carry anti-inflammatory and anti-fibrotic signals. In a laboratory study, topical application of these exosomes to damaged corneas led to faster wound closure, lower haze scores, and reduced fibrosis markers compared to controls.17PubMed Central. Mesenchymal Stem Cell Exosomes as Immunomodulatory Therapy for Corneal Scarring The appeal here is that exosomes can be manufactured in a lab without needing to transplant live cells into the eye, potentially sidestepping some of the safety and regulatory hurdles of cell therapy.
Gene Therapy on the Horizon
Gene therapy for corneal scarring is still experimental, but the early results are intriguing. Most approaches target the same TGF-β pathway. One strategy uses a molecule called decorin, a natural protein that binds TGF-β and prevents it from reaching its receptors on fibroblasts. Nanoparticle-delivered decorin genes have blocked the transformation of human corneal fibroblasts into myofibroblasts in lab dishes, and in a rabbit model of corneal fibrosis, viral delivery of a different anti-fibrotic gene called Smad7 safely and effectively inhibited scarring.18Current Gene Therapy. Gene Therapy in the Anterior Eye Segment – Section: Corneal and Conjunctival Fibrosis and Scarring
None of these gene therapies are available in clinics yet. The leap from animal models to approved human treatments is long, and the eye adds its own regulatory complexity because any inadvertent damage could permanently affect vision. Still, the research illustrates that corneal scarring is increasingly understood as a treatable molecular process, not an irreversible structural fait accompli.
Living With a Scar You Cannot Fully Remove
Not every corneal scar needs to be surgically removed to improve vision. Scleral contact lenses, which are large rigid lenses that vault entirely over the cornea and rest on the white of the eye, can mask the optical effects of a scar by creating a smooth, uniform refracting surface in front of it. They also keep the cornea continuously hydrated, which helps with comfort if the scarred surface is irregular or prone to dryness. Scleral lenses are often used alongside other therapies, serving as a bridge while someone waits for surgery or as a long-term solution when surgery carries too much risk.
For mild scars that sit outside the visual axis, no treatment may be needed at all. A peripheral scar can be cosmetically noticeable but optically harmless. In those cases, the question shifts from “can this be removed?” to “does this actually need to be removed?” Your ophthalmologist can map the scar’s position relative to your pupil and help you decide whether intervention is worth the risks.
The Scale of the Problem
Corneal disease and injury are the second most common cause of blindness worldwide, affecting over ten million people. About 90 percent of that blindness is permanent because of scarring and abnormal blood vessel growth in the cornea.19PubMed Central. Control of scar tissue formation in the cornea: strategies in clinical and corneal tissue engineering Those numbers put the question of scar removal in a different light: this is not a niche cosmetic concern but a major public health issue, particularly in parts of the world where infectious keratitis is common and access to surgical intervention is limited.
The global shortage of donor corneas makes the situation worse. Even where the surgical expertise exists to perform a transplant, the tissue may not be available. This scarcity is a significant driver of research into biosynthetic corneas, cell-based therapies, and anti-fibrotic drugs, all of which could eventually reduce the dependence on donor tissue.
Scars Elsewhere on the Eye
Not all eye scars are corneal. The conjunctiva, the thin membrane covering the white of the eye, can also scar after surgery, infection, or chronic inflammation. A common example involves pterygium excision, where a wing-shaped growth is removed from the conjunctiva. Surgeons sometimes apply a drug called mitomycin C during the procedure to reduce scarring and recurrence, though even with it, some patients develop granulomas or recurrent tissue growth.20PubMed Central. Recurrence rate with use of intraoperative Mitomycin C versus Conjunctival Autograft following pterygium excision Conjunctival scars affect the eye differently from corneal scars: they are less likely to impair central vision directly but can cause chronic irritation, restrict eye movement, or complicate future surgeries if the scarring is extensive.
Retinal scars are another category entirely. Scarring on the retina, whether from macular degeneration, diabetic eye disease, or trauma, cannot be treated with the surface-based techniques described above. The retina sits at the back of the eye and is far more delicate and less accessible. Retinal scars currently have even fewer treatment options than corneal ones, and full reversal is not yet possible with any available therapy. If you have been told you have a scar “on the eye,” getting clarity on whether the scar is corneal, conjunctival, or retinal is the single most important step in understanding your options.
When Scars Come Back After Treatment
One frustrating reality is that treating a corneal scar does not guarantee it stays gone. Any procedure that wounds the cornea can itself trigger the same fibrotic cascade that caused the original scar. PTK, keratectomy, and transplantation all carry some risk of recurrent haze or scarring during healing. This is why adjunctive treatments like amniotic membrane grafts, mitomycin C applied briefly during surgery, and experimental anti-TGF-β drugs are used alongside mechanical scar removal: they try to quiet the wound-healing response so the cornea heals transparently rather than forming a new scar over the old one.
Transplanted corneas face their own version of this problem. Even a perfectly clear donor graft can gradually develop haze if the body’s immune response triggers low-grade chronic inflammation, or if the underlying disease (like a corneal dystrophy) recurs in the new tissue. Regular follow-up and, in many cases, long-term steroid eye drops are part of managing a transplant to keep it clear.